Drug intelligence / Profile preview

DWC20161

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWC20161 is a small molecule investigational drug developed by Daewoong Pharmaceutical. It has been studied in phase 1 clinical trials, primarily to assess drug-drug interactions in healthy volunteers. The specific mechanism of action, molecular target, and therapeutic indications for DWC20161 have not been publicly disclosed as of June 2025. There are no known approved indications or regulatory approvals for this compound[1][3][4].

Other names: DWC-20161DWC20161DWC 20161

Beyond the preview

Go deeper on DWC20161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC20161.

Explore the full profile